



MOBILE THERAPEUTIC ATTENTION FOR PATIENTS WITH TREATMENT RESISTANT SCHIZOPHRENIA



“We hope that m-RESIST will bring a real benefit for people with treatment-resistant schizophrenia by extending the area of application of the personalized pharmacological and psychological treatment, not only improving the persistence of care and the participation of the caregivers, but also by creating a broad database to allow development in characterising the profile of the people with treatment-refractory schizophrenia”.

The m-RESIST Clinical Team

Contact

Project Coordinator  
Margarita Hospedales Salomó  
TICSALUT Foundation (Spain)  
mhospedales@ticsalut.cat

Follow us

www.mresist.eu  
mResist\_eu  
mResist

Partners



This project is co-funded by the Horizon 2020 Framework Programme of the European Union under grant agreement no [643552].



MOBILE THERAPEUTIC ATTENTION FOR PATIENTS WITH TREATMENT RESISTANT SCHIZOPHRENIA

# WHAT IS SCHIZOPHRENIA?

Schizophrenia is a complex multifaceted mental illness that features psychotic, negative, affective and cognitive symptoms. Sufferers deal with anxiety, depression, attention deficit and low motivation



In European Union approximately 5 million people suffer from psychotic disorders.

Between 30% and 50% of people suffering from schizophrenia are treatment-resistant cases

High suicide risk and low insight are characteristic symptoms

## Refractory Schizophrenia means:



Higher emotional distress



Highly persistent symptoms



Long periods of hospital attention



Greater risk of mortality and multi morbidity

# ISSUES TO BE ADDRESSED

Standard treatment is not sufficient enough  
Find new means of treating this severe brain disorder which cause marked impairments in social, occupational, and cognitive functioning

## TARGET AUDIENCES



## WHAT m-RESIST AIMS TO OFFER?



Model of analysis to move forward in understanding treatment-resistant schizophrenia



Innovative Disease Management System



Mobile ICT system addressed to empower Patients and caregivers

BY

actively participating in the therapeutic process & self-managing their condition

## THE m-RESIST APPROACH:

Use of m-RESIST integrated care program

Use of Big Data mining tools

← IN ORDER TO Use of Predictive model


Optimise & personalise patient's treatment, ensuring immediacy and continuity of care and improve current healthcare processes

The collaboration of caregivers, patient's families and professionals would enable the provision of specific support services and would prevent acute symptoms

## THE m-RESIST

The innovative disease management system consists of different parts of development

Designing and developing the m-RESIST system.



Designing the m-RESIST program (services, care pathways or health routes)




Testing the m-RESIST system & program on healthy volunteers, patients and caregivers



Promoting the active role of patients, caregivers, clinicians in the design & assessment of the m-RESIST program & tools



Creating a predictive model to identify risks & gaps in the treatments enabling the prescription of personalized treatment & tools for patients



# STEP BY STEP

